However, targeted therapy against CD44 faces clinical constraints, such as the complexity of CD44 variations and downstream signals coupled with tumor heterogeneity, the low affinity of CD44 monoclonal antibodies, the emergence of drug resistance, and severe skin toxicity due to the disruption of normal physiological functions (10, 15). Here, CD44 is linked to neoplasm.